Peter Elliott | |
|---|---|
 | |
| Born | Peter John Elliott August 19, 1958 |
| Nationality | British |
| Alma mater | London University (Chelsea College) Cambridge University (Trinity College) |
| Scientific career | |
| Fields | Pharmacology, Drug Development |
| Institutions | Wapiti Pharmaceutical Consulting |
Peter Elliott (born August 19, 1958) is a British pharmacologist and drug developer who has initiated clinical trials across a range of disease areas, and is the co-developer of Velcade, a drug used to treat multiple myeloma.
Elliott was born in Cardiff, Wales and attended Llanishen High school before being accepted to study pharmacology at Chelsea College, University of London (1979-1981).[ citation needed ] During this period he spent a year gaining research experience at The Medical Clinic, Tubingen, Germany, working with Peter A. Berg [1] on the autoimmune disease, Primary biliary cholangitis (1978-1980). After graduating, Elliott embarked upon a Ph.D., under the supervision of Leslie and Susan Iversen at Cambridge University, [2] [3] where he was a member of Trinity College (1981-1984). His research focused on the behavioural effects of neurokinins on catecholamine systems and was carried out at the Department of Psychology, and the Medical Research Council's (MRC) Neurochemical Pharmacology Unit (NCPU), at Addenbrookes Hospital. During his Ph.D., Elliott published seven research papers, including in the scientific journals, Nature and Science.[ citation needed ] The Nature paper was one of the first publications to utilize monoclonal antibodies as pharmaceutical tools. The monoclonal antibody to Substance P, used in the paper, was generated from an adjacent laboratory of César Milstein. [4] [5]
In 1984, Elliott was granted a research Fellowship to work with Charles B. Nemeroff at the Department of Psychiatry, Duke University. [6] There he investigated the role of neurotensin on dopamine systems in the central nervous system, in relation to psychiatric disorders such as schizophrenia. The following year he moved to Yale University & The Connecticut Mental Health Center to work with Michael J. Bannon (1985-1986) [7] to investigate the effects of neurokinins on molecular aspects of dopamine systems, and their potential role in psychiatry, and in particular, their ability to modulate the tardive dyskinesias elicited by certain neuroleptics. Subsequently, Elliott took a post-doctoral position in the Pharmacology Department, McGill University (1986-1988) where he focused on animal models of Alzheimer's disease, as well as developing new monoclonal antibodies for research purposes. During his tenure at McGill, Elliott was also invited to spend time, as a visiting scholar, with Erminio Costa [8] at the FIDIA-Georgetown University Institute for Neuroscience, where he explored the ability of nerve growth factor to modulate/repair degenerative diseases of the central nervous system.
Elliott then moved into the pharmaceutical-biotechnology arena where he worked on developing drugs to treat conditions including inflammation, diabetes, pain and cancer. [9] [10] [11] [12] [13] Elliott has over 300 publications in journals including Nature, Science, Cell, P.N.A.S., J. Medicinal Chemistry, Brain Research, Neuroscience, Blood, Cancer Research, and J. Clinical Oncology. [9] [10] [11] [12] [13]
During the second year at McGill, Elliott was recruited to Glaxo Group Research, in the UK (now GlaxoSmithKline) to head up their Parkinson's and Movement Disorder group. During this time (1988-1993), he also worked on preclinical aspects of the drug, Ondansetron (a novel and first in class antiemetic drug), as well as exploring novel non-opioid opportunities to develop drugs to treat pain.[ citation needed ] Elliott co-authored the Glaxo Pocket Guide to Pharmacology [14] during this period. In 1993, Elliott was hired by the biotechnology company, Alkermes Inc. as head of Pharmacology (1993-1996) [15] where he focused on novel drugs to treat stroke, and also on a permeabilizing agent, RMP-7, that enabled other drugs to treat glioma, and opportunistic infections in AIDS patients. In 1996, he was offered the head of Pharmacology at the biotechnology company, ProScript (1996-2001), where, along with Julian Adams, [16] he co-developed a novel, anti-cancer agent, Velcade (PS-341), currently used to treat multiple myeloma. The clinical program was supported by National Cancer Institute (NCI; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Program). [17] ProScript was ultimately merged with LeukoSite, and then acquired by Millennium Pharmaceuticals (MLNM [18] - now Takeda [19] ) for $635mm. [20] MLNM was subsequently purchased by Takeda who currently market Velcade. Throughout this time, Elliott led the clinical development of PS-341 until its final Phase III trial when it was approved by the FDA, and other regulatory authorities around the world.[ citation needed ] Elliott was also the project leader of an anti-stroke agent, PS-519, that completed Phase IIa clinical trials. Support for the development of PS-519 was, in part, achieved by Elliott being awarded a $100,000 SBIR grant, [21] and a CRADA contract with the Walter Reed Army Institute of Research.
When leaving Millennium, Elliott was Senior Vice President of Pharmacology & Drug Development.[ citation needed ] Following the launch of Velcade, Elliott joined a new biotechnology company, CombinatoRx (CRx) as Executive Vice President of Product Development (2001-2005). [22] Here he launched numerous combination products into various inflammatory areas (asthma, psoriasis, rheumatoid arthritis) and oncology. During his time at CRx, Elliott was part of the management team that completed a successful $42 MM IPO [23] as well as gaining $20 MM support from the Singaporean government to start up a new company in Singapore to mimic the CRx model in the USA. [24] [25] [26] [27] In 2005, Peter was recruited to another biotechnology company, Sirtris (2005-2009). [28] [29] The company focused on diseases of ageing including diabetes, oncology and inflammatory conditions. Elliott was part of the management team that completed a $60 MM IPO, [30] and additional rounds of funding. He completed clinical trials in diabetics before the company was acquired by GSK in 2008 for $720 MM. [31] Elliott remained for the transition period, and then left in 2009, at this time he was Head of Research and Development. [32] [33] [34] [35] Subsequently, Elliott set up his own consulting company, Wapiti Pharmaceutical Consulting, Marlboro, MA, USA.[ citation needed ]
Elliott is the co-author of patents relating to procedures and drugs worked on during his time in academia and within the industrial setting. [36] [37] [38] [39]
Elliott married Laura Bird (b 1957. d 2010) in 1983 and has a daughter and a son.[ citation needed ]
Labcorp Drug Development presently known as Fortrea is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is spin-off from Labcorp, which employs more than 70,000 people worldwide.
Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Nefazodone, sold formerly under the brand names Serzone, Dutonin, and Nefadar among others, is an atypical antidepressant medication which is used in the treatment of depression and for other uses. Nefazodone is still available in the United States, but was withdrawn from other countries due to rare liver toxicity. The medication is taken by mouth.
Ropinirole, sold under the brand name Requip among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). It is taken by mouth.
Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.
Vanoxerine is an investigational drug which is being evaluated for the treatment of heart arrhythmias and cocaine dependence. Vanoxerine is a piperazine derivative which has multiple pharmacological activities including acting as an dopamine reuptake inhibitor, serotonin transporter inhibitor, and as a blocker of the cardiac hERG repolarizing potassium channel (IKr).
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Conceived in 2004 by Harvard University biologist David Sinclair and Andrew Perlman, and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel, the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab.
Christoph Westphal is an American biomedical businessman.
Nicholas B. Lydon FRS is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.
Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
Harvey J. Berger is an American physician-scientist, entrepreneur and biotechnology executive. He was the founder and chairman and chief executive officer of ARIAD Pharmaceuticals, Inc. for 25 years, starting in 1991 and became advisor to the board in 2016. He was also executive chairman at Medinol, Inc from 2017 to 2018. In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees.
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.